Oxidative stress induced by Etoposide anti-cancer chemotherapy drives the emergence of tumor-associated bacteria resistance to fluoroquinolones

J Adv Res. 2024 Jan:55:33-44. doi: 10.1016/j.jare.2023.02.011. Epub 2023 Feb 21.

Abstract

Introduction: Antibiotic-resistant bacterial infections, such as Pseudomonas aeruginosa and Staphylococcus aureus, are prevalent in lung cancer patients, resulting in poor clinical outcomes and high mortality. Etoposide (ETO) is an FDA-approved chemotherapy drug that kills cancer cells by damaging DNA through oxidative stress. However, it is unclear if ETO can cause unintentional side effects on tumor-associated microbial pathogens, such as inducing antibiotic resistance.

Objectives: We aimed to show that prolonged ETO treatment could unintendedly confer fluoroquinolone antibiotic resistance to P. aeruginosa, and evaluate the effect of tumor-associated P. aeruginosa on tumor progression.

Methods: We employed experimental evolution assay to treat P. aeruginosa with prolonged ETO exposure, evaluated the ciprofloxacin resistance, and elucidated the gene mutations by DNA sequencing. We also established a lung tumor-P. aeruginosa bacterial model to study the role of ETO-evolved intra-tumoral bacteria in tumor progression using immunostaining and confocal microscopy.

Results: ETO could generate oxidative stress and lead to gene mutations in P. aeruginosa, especially the gyrase (gyrA) gene, resulting in acquired fluoroquinolone resistance. We further demonstrated using a microfluidic-based lung tumor-P. aeruginosa coculture model that bacteria can evolve ciprofloxacin (CIP) resistance in a tumor microenvironment. Moreover, ETO-induced CIP-resistant (EICR) mutants could form multicellular biofilms which protected tumor cells from ETO killing and enabled tumor progression.

Conclusion: Overall, our preclinical proof-of-concept provides insights into how anti-cancer chemotherapy could inadvertently allow tumor-associated bacteria to acquire antibiotic resistance mutations and shed new light on the development of novel anti-cancer treatments based on anti-bacterial strategies.

Keywords: Antibiotic resistance; Cancer; Microfluidics; Mutation; Oxidative stress; Pseudomonas aeruginosa.

MeSH terms

  • Anti-Bacterial Agents / pharmacology
  • Ciprofloxacin / pharmacology
  • Etoposide / pharmacology
  • Etoposide / therapeutic use
  • Fluoroquinolones / pharmacology
  • Humans
  • Lung Neoplasms* / drug therapy
  • Microbial Sensitivity Tests
  • Oxidative Stress
  • Pseudomonas Infections* / microbiology
  • Tumor Microenvironment

Substances

  • Fluoroquinolones
  • Anti-Bacterial Agents
  • Etoposide
  • Ciprofloxacin